Revenue, R&D spend and profit for the pharma, biotech, medtech and research groups with operations in Ireland, from their own annual reports, and the Irish companies each group has registered.
Johnson & Johnson reported the largest revenue of the US-dollar reporters, $94.19bn for the year to Dec 2025, according to its annual report filed with the US Securities and Exchange Commission. Across the 40 groups here that report both revenue and R&D, the median company spent 16.3% of revenue on research and development, and BioNTech SE spent the highest share, 73.3%. Figures are copied from each group's XBRL financial statements in the currency it reports in; companies reporting in euro, pounds, kroner or yen are listed separately rather than converted.
R&D expense divided by revenue, both as reported in the latest annual report. The share does not depend on currency, so every group can be compared.
Not charted because R&D spending was larger than revenue, as is normal for companies whose products are still in development: Autolus Therapeutics plc ($118m R&D, $75.4m revenue), Bicycle Therapeutics plc ($240m R&D, $72.6m revenue), Mereo BioPharma Group plc ($17.8m R&D, $500,000 revenue), Moderna, Inc. ($3.13bn R&D, $1.94bn revenue), Silence Therapeutics plc ($67.8m R&D, $559,000 revenue).
Contract research organisations (ICON, IQVIA, Charles River) do not report a separate R&D line, so they are not in this chart. Some companies tag R&D excluding acquired in-process R&D; the company pages say where that applies.
| Company | Revenue | Change | R&D | R&D % | Net income | Year to |
|---|---|---|---|---|---|---|
| Johnson & Johnson US GAAP · 10-K · 20 Irish companies |
$94.19bn | +6.0% | $14.67bn | 15.6% | $26.80bn | Dec 2025 |
| Eli Lilly and Company US GAAP · 10-K · 4 Irish companies |
$65.18bn | +44.7% | $13.34bn | 20.5% | $20.64bn | Dec 2025 |
| Merck & Co., Inc. (MSD) US GAAP · 10-K · 12 Irish companies |
$65.01bn | +1.3% | $15.79bn | 24.3% | $18.25bn | Dec 2025 |
| Pfizer Inc. US GAAP · 10-K · 14 Irish companies |
$62.58bn | -1.6% | $10.44bn | 16.7% | $7.77bn | Dec 2025 |
| AbbVie Inc. US GAAP · 10-K · 8 Irish companies |
$61.16bn | +8.6% | $9.10bn | 14.9% | $4.23bn | Dec 2025 |
| AstraZeneca PLC IFRS · 20-F · 4 Irish companies |
$58.74bn | +8.6% | $14.23bn | 24.2% | $10.23bn | Dec 2025 |
| Novartis AG IFRS · 20-F · 3 Irish companies |
$54.53bn | +8.4% | $11.20bn | 20.5% | $13.98bn | Dec 2025 |
| Bristol-Myers Squibb Company US GAAP · 10-K · 9 Irish companies |
$48.19bn | -0.2% | $9.95bn | 20.6% | $7.05bn | Dec 2025 |
| Thermo Fisher Scientific Inc. US GAAP · 10-K · 6 Irish companies |
$44.56bn | +3.9% | $1.40bn | 3.1% | $6.70bn | Dec 2025 |
| Abbott Laboratories US GAAP · 10-K · 13 Irish companies |
$44.33bn | +5.7% | $2.94bn | 6.6% | $6.52bn | Dec 2025 |
| Amgen Inc. US GAAP · 10-K · 4 Irish companies |
$36.75bn | +10.0% | $7.27bn | 19.8% | $7.71bn | Dec 2025 |
| Medtronic plc US GAAP · 10-K · 8 Irish companies |
$36.36bn | +8.4% | $2.87bn | 7.9% | $4.80bn | Apr 2026 |
| Gilead Sciences, Inc. US GAAP · 10-K · 4 Irish companies |
$29.44bn | +2.4% | $5.80bn | 19.7% | $8.51bn | Dec 2025 |
| Stryker Corporation US GAAP · 10-K · 15 Irish companies |
$25.12bn | +11.2% | $1.62bn | 6.5% | $3.25bn | Dec 2025 |
| Danaher Corporation US GAAP · 10-K · 3 Irish companies |
$24.57bn | +2.9% | $1.60bn | 6.5% | $3.61bn | Dec 2025 |
| Boston Scientific Corporation US GAAP · 10-K · 4 Irish companies |
$20.07bn | +19.9% | $2.05bn | 10.2% | $2.89bn | Dec 2025 |
| IQVIA Holdings Inc. US GAAP · 10-K · 2 Irish companies |
$16.31bn | +5.9% | — | — | $1.36bn | Dec 2025 |
| Regeneron Pharmaceuticals, Inc. US GAAP · 10-K · 1 Irish company |
$14.34bn | +1.0% | $5.85bn | 40.8% | $4.50bn | Dec 2025 |
| Viatris Inc. US GAAP · 10-K · 13 Irish companies |
$14.30bn | -3.0% | $966m | 6.8% | −$3.51bn | Dec 2025 |
| Vertex Pharmaceuticals Incorporated US GAAP · 10-K · 4 Irish companies |
$12.00bn | +8.9% | $3.91bn | 32.6% | $3.95bn | Dec 2025 |
| Baxter International Inc. US GAAP · 10-K · 6 Irish companies |
$11.24bn | +5.7% | $518m | 4.6% | −$957m | Dec 2025 |
| Biogen Inc. US GAAP · 10-K · 2 Irish companies |
$9.89bn | +2.2% | $1.78bn | 18.0% | $1.29bn | Dec 2025 |
| Zoetis Inc. US GAAP · 10-K · 2 Irish companies |
$9.47bn | +2.3% | $698m | 7.4% | $2.67bn | Dec 2025 |
| ICON plc US GAAP · 20-F · 9 Irish companies |
$8.25bn | +0.8% | — | — | $229m | Dec 2025 |
| Smith & Nephew plc IFRS · 20-F · 1 Irish company |
$6.16bn | +6.1% | $296m | 4.8% | $625m | Dec 2025 |
| Edwards Lifesciences Corporation US GAAP · 10-K · 2 Irish companies |
$6.07bn | +11.5% | $1.08bn | 17.8% | $1.07bn | Dec 2025 |
| Bausch + Lomb Corporation US GAAP · 10-K · 2 Irish companies |
$5.10bn | +6.5% | $371m | 7.3% | −$360m | Dec 2025 |
| Illumina, Inc. US GAAP · 10-K · 1 Irish company |
$4.34bn | -0.7% | $967m | 22.3% | $850m | Dec 2025 |
| Jazz Pharmaceuticals plc US GAAP · 10-K · 9 Irish companies |
$4.27bn | +4.9% | $783m | 18.3% | −$356m | Dec 2025 |
| argenx SE IFRS · 20-F |
$4.15bn | +89.9% | $1.36bn | 32.9% | $1.29bn | Dec 2025 |
| Charles River Laboratories International, Inc. US GAAP · 10-K · 3 Irish companies |
$4.02bn | -0.9% | — | — | −$144m | Dec 2025 |
| Genmab A/S IFRS · 20-F |
$3.72bn | +19.2% | $1.61bn | 43.2% | $963m | Dec 2025 |
| QIAGEN N.V. US GAAP · 20-F |
$2.09bn | +5.7% | $188m | 9.0% | $425m | Dec 2025 |
| Teleflex Incorporated US GAAP · 10-K · 10 Irish companies |
$1.99bn | +17.2% | $145m | 7.3% | −$906m | Dec 2025 |
| Moderna, Inc. US GAAP · 10-K |
$1.94bn | -39.9% | $3.13bn | 161.1% | −$2.82bn | Dec 2025 |
| LivaNova PLC US GAAP · 10-K |
$1.39bn | +10.7% | $186m | 13.4% | −$242m | Dec 2025 |
| Indivior Pharmaceuticals, Inc. US GAAP · 10-K · 1 Irish company |
$1.24bn | +4.3% | $97.0m | 7.8% | $210m | Dec 2025 |
| Autolus Therapeutics plc US GAAP · 10-K |
$75.4m | +644.9% | $118m | 156.1% | −$288m | Dec 2025 |
| Bicycle Therapeutics plc US GAAP · 10-K |
$72.6m | +105.8% | $240m | 331.0% | −$219m | Dec 2025 |
| Silence Therapeutics plc US GAAP · 10-K |
$559,000 | -98.7% | $67.8m | >999% | −$88.6m | Dec 2025 |
| Mereo BioPharma Group plc US GAAP · 10-K |
$500,000 | — | $17.8m | >999% | −$41.9m | Dec 2025 |
"Change" is revenue against the previous financial year, from the same filings. "R&D %" is R&D expense divided by revenue. Net income is the profit attributable to the company's shareholders where the filing tags it, otherwise total profit.
| Company | Revenue | Change | R&D | R&D % | Net income | Year to |
|---|---|---|---|---|---|---|
| Novo Nordisk A/S IFRS · 20-F · 2 Irish companies |
DKK 309.1bn | +6.4% | DKK 52.04bn | 16.8% | DKK 102.4bn | Dec 2025 |
| Sanofi IFRS · 20-F · 3 Irish companies |
€43.63bn | +6.2% | €7.84bn | 18.0% | €7.81bn | Dec 2025 |
| Grifols, S.A. IFRS · 20-F · newer 20-F filed, not yet in SEC data · 3 Irish companies |
€7.21bn | +9.4% | €384m | 5.3% | €157m | Dec 2024 |
| BioNTech SE IFRS · 20-F |
€2.87bn | +4.3% | €2.10bn | 73.3% | −€1.14bn | Dec 2025 |
| GSK plc IFRS · 20-F · 6 Irish companies |
£32.67bn | +4.1% | £7.53bn | 23.0% | £5.72bn | Dec 2025 |
| Haleon plc IFRS · 20-F · 3 Irish companies |
£11.03bn | -1.8% | £316m | 2.9% | £1.67bn | Dec 2025 |
| Takeda Pharmaceutical Company Limited IFRS · 20-F · newer 20-F filed, not yet in SEC data · 6 Irish companies |
¥4,581.6bn | +7.5% | ¥730.2bn | 15.9% | ¥107.9bn | Mar 2025 |
These groups file 20-F annual reports under IFRS in their home currency (euro, pounds sterling, Danish kroner or Japanese yen). The figures are not converted, so compare them within a currency, or use the percentages.
Each company page lists the Irish companies by name, with CRO number, type and the date of the last accounts filed. A company is counted when GLEIF's legal entity register links it to the group as its ultimate parent, or when we matched its name and registered address by hand; dissolved companies are not counted. Holding, finance and treasury companies are included, so the count reflects how a group is structured in Ireland, not how many sites or staff it has here.
What these figures are. Revenue, R&D expense and net income are the values each group tagged in the XBRL financial statements of its annual report (10-K, or 20-F for foreign private issuers) filed with the SEC, taken from the SEC's companyfacts data. Each year comes from the most recent annual report that includes it, so earlier years reflect any restatement; every figure links to its filing. Groups that do not file with the SEC (for example Roche, Bayer or Eurofins) have no financial figures here, but their Irish companies are listed. Financial years follow each company's own calendar: Medtronic's ends in April and Takeda's in March. This is reference data, not investment advice.
Every financial figure is the value the company itself filed. Percentages and year-on-year changes are calculated here from those values and labelled as such.
A weekly job downloads each group's SEC companyfacts file, GLEIF relationship records and the matching CRO rows, and stores them. The list of companies and their SEC and LEI identifiers is kept by hand. No AI drafting and no editorial pass. See our editorial standards. The the SEC, GLEIF and the CRO data on this page was last retrieved on 30 Sep 2026.